Pro - inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in guillain - barre syndrome

Basit Öğe Kaydı
dc.contributor.authorHasan Tekgül
dc.contributor.authorNecil Kütükçüler
dc.contributor.authorSuat Çağlayan
dc.contributor.authorSeranur Tütüncüoğlu
dc.date.accessioned2019-10-26T19:54:01Z
dc.date.available2019-10-26T19:54:01Z
dc.date.issued1998
dc.departmentEge Üniversitesien_US
dc.description.abstractBoth cell-mediated immunity and humoral factors are involved in the pathogenesis of Guillain-Barre syndrome (GBS). Intravenous immunoglobulin (IVIG) has been reported to be a practical, effective and safe treatment in childhood GBS, although the mode of action of IVIG remains uncertain. We studied pro-inflammatory cytokines (interleukin-2, interleukin-1<$\alpha$ and tumor necrosis factor-$\alpha$) in plasma and cerebrospinal fluid (CSF) and lymphocyte subsets in peripheral blood both in the acute phase and in the recovery period in six children with GBS treated with IVIG. Flow cytometry was used to determine the subsets of lymphocytes in peripheral blood, and cytokines analyses were performed by using ELISA technique. Results were compared with a control group of 20 healthy children. A standard protocol of IVIG (400 mg/kg/day for 5 days) was administered to all the patients. Plasma interleukin-2 concentrations and the number of HLA DR+ active T cells in peripheral blood were significantly higher in the acute phase of the disease than in the recovery period and in healthy controls. There was no significant difference in the other cytokine concentrations in plasma and CSF or in the other lymphocyte subsets in peripheral blood. Our data indicate that IVIG may provide its possible theurapeutic effect by acting in the cell-mediated immunity in GBS patients.en_US
dc.description.abstractBoth cell-mediated immunity and humoral factors are involved in the pathogenesis of Guillain-Barre syndrome (GBS). Intravenous immunoglobulin (IVIG) has been reported to be a practical, effective and safe treatment in childhood GBS, although the mode of action of IVIG remains uncertain. We studied pro-inflammatory cytokines (interleukin-2, interleukin-1<$\alpha$ and tumor necrosis factor-$\alpha$) in plasma and cerebrospinal fluid (CSF) and lymphocyte subsets in peripheral blood both in the acute phase and in the recovery period in six children with GBS treated with IVIG. Flow cytometry was used to determine the subsets of lymphocytes in peripheral blood, and cytokines analyses were performed by using ELISA technique. Results were compared with a control group of 20 healthy children. A standard protocol of IVIG (400 mg/kg/day for 5 days) was administered to all the patients. Plasma interleukin-2 concentrations and the number of HLA DR+ active T cells in peripheral blood were significantly higher in the acute phase of the disease than in the recovery period and in healthy controls. There was no significant difference in the other cytokine concentrations in plasma and CSF or in the other lymphocyte subsets in peripheral blood. Our data indicate that IVIG may provide its possible theurapeutic effect by acting in the cell-mediated immunity in GBS patients.en_US
dc.identifier.endpage363en_US
dc.identifier.issn0041-4301
dc.identifier.issue3en_US
dc.identifier.startpage357en_US
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TmpNNE16TT0=
dc.identifier.urihttps://hdl.handle.net/11454/14035
dc.identifier.volume40en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Pediatricsen_US
dc.relation.publicationcategoryDiğeren_US]
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPediatrien_US
dc.titlePro - inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in guillain - barre syndromeen_US
dc.typeOtheren_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu